| Literature DB >> 28159159 |
Abstract
Respiratory syncytial virus (RSV) is the single most important cause of severe respiratory infection in very young infants. It has also been recently recognized as a significant cause of severe illness in elderly adults, those with underlying cardiopulmonary disease, and the immunocompromised. RSV is suspected of playing a major role in the development of asthma. Prophylaxis in high-risk infants using a monoclonal antibody is the only effective specific therapy available but recent breakthroughs in vaccine design and antiviral drugs offer the promise of effective prophylactic and therapeutic agents against RSV.Entities:
Keywords: Adults; Antivirals; Asthma; Bronchiolitis; Chronic obstructive pulmonary disease; Respiratory syncytial virus; Vaccines
Mesh:
Substances:
Year: 2016 PMID: 28159159 PMCID: PMC5844562 DOI: 10.1016/j.ccm.2016.11.010
Source DB: PubMed Journal: Clin Chest Med ISSN: 0272-5231 Impact factor: 2.878